Plak Tip Psöriazisde Düşük Doz Metotreksat ile İndüklenen Perilezyonel Büllöz Eritem
Author(s) -
Pelin Üstüner,
Nursel Dılek,
Yunus Saral
Publication year - 2016
Publication title -
the annals of clinical and analytical medicine
Language(s) - English
Resource type - Journals
ISSN - 2667-663X
DOI - 10.4328/jcam.1754
Subject(s) - medicine
The bullous variant of chemotherapy-induced acral erythema has been reported with methotrexate and more frequently cytosine arabinoside. However, perilesional bullous erythema in association with methotrexate hasn%u2019t been reported before. Herein, we presented a 64-year-old male patient, a biopsy proven case of generalized plaque psoriasis, who developed a bullous perilesional erythema after a single oral dose of 15 mg/week methotrexate. The patient developed symmetrical, well-demarcated, painful, erythematous perilesional bullous lesions surrounding these psoriasiform plaques within 3 days of receiving the medication. The lesions were unresponsive to the potent topical corticosteroids and wet dressings. After 3 weeks the topical corticosteroids were discontinued and methotrexate dose was reduced to 10 mg/week. As a result of the permanency of the bullous perilesional erythema, a topical herbal therapy including a henna extract %u201CLawsonia inermis%u201D was started for an anti-inflammatory response. The lesions gradually improved and resolved almost completely with residual hyperpigmentation within two weeks. We believe that, perilesional bullous erythema may be seen rarely in psoriatic patients treated with methotrexate and there is no need for discontinuation of methotrexate therapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom